The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021).
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021
Get Sample Copy Here@ www.reportsnreports.com/contacts/r…aspx?name=232420
Over the years, the nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals.
The market is in its growth phase with an increasing number of radioisotope approvals for different clinical indications. Ra-223, I-131, and Y-90 ensured their leading position in the nuclear medicine therapeutic market.
Factors such as advances in radiotracers and increasing incidence and prevalence of cancer and cardiac ailments, introduction of alpha emitters for targeted cancer therapy, high demand for radiopharmaceuticals in emerging markets, upcoming radio isotopes, and increasing new product launches by industry players are expected to drive the nuclear medicine/radiopharmaceuticals market in the coming years. However, the shutdown of major nuclear reactors, which are the main source for radiopharmaceutical production, is a major challenge for the growth of the market.
In 2016, North America is expected to account for the largest share of the global nuclear medicine/radiopharmaceuticals market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is projected to have the highest growth rate in the forecast period.
Nuclear Medicine Market, By Application
Other SPECT Applications
Other PET Applications
Other Therapeutic Applications
Nuclear Medicine Market, By Procedural Volume
Fundamental from Table of Content
3 Executive Summary
4 Premium Insights
4.1 Nuclear Medicine/Radiopharmaceuticals: Market Overview
4.2 Geographic Analysis: Nuclear Medicine Market, By PET Application (2016)
4.3 Nuclear Medicine Market, By Type (2016 vs 2021)
4.4 Geographical Snapshot of the Nuclear Medicine Market
Get complete full Report with TOC here: www.reportsnreports.com/contacts/i….aspx?name=232420
12 Company Profiles
(Overview, Products and Services, Financials, Strategy & Development)*
12.2 Cardinal Health, Inc.
12.3 Mallinckrodt PLC
12.4 GE Healthcare (A Fully Owned Subsidiary of General Electric Company)
12.5 Lantheus Medical Imaging, Inc.
12.6 Bayer AG
12.7 Bracco Imaging S.P.A
12.8 Eczacibasi-Monrol Nuclear Products
12.9 Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)
12.10 Advanced Accelerator Applications S.A.
12.11 IBA Molecular
*Details on Overview, Products and Services, Financials, Strategy & Development Might Not Be Captured in Case of Unlisted Companies.